BioCentury
ARTICLE | Financial News

Gilead beats Street, raises guidance

October 24, 2012 1:20 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) increased its full-year sales guidance to $9.1-9.2 billion from $8.8-9.0 billion after reporting 3Q12 financial results on Tuesday that beat the Street's estimates. Non-GAAP diluted EPS for the quarter was $1, beating by $0.06 the Street's estimate, but down from $1.02 in 3Q11. Revenues grew 14% to $2.4 billion, above the Street's estimate of $2.3 billion. Gilead, which made the announcement after market close, was down $1.47 to $64.91 on Tuesday. ...